A Key Driver of Prostate Cancer Discovered
Written By: Aidan Abney
October 16, 2026
A couple of weeks ago in October, researchers at Fred Hutch Cancer Center just found a single RNA that is responsible for controlling and measuring the frequency of prostate cancer cells. Previously conceptualized in most of cell biology as a separate biological marker for gene regulation, it is now understood to play a major role in how prostate cancer adapts to treatment.
Prostate Cancer thrives off androgen receptors, and up to the point when the cancer becomes too invasive, it shifts to an androgen receptor-independent state, which aids the tumor cell(s) in becoming resistant to therapy, therefore making them more aggressive and dangerous - which is otherwise known as lineage plasticity. This is one of the most critical stages of cancer progression, and it can mean, literally, either life or death for a patient (if this becomes the case).
In molecular biology, tRNA, small RNA molecules, were thought to be the standard organizer during protein synthesis, but in recent years, tRNA does, in fact, play a significant role in cell death, metabolic rewiring, and changing the landscape of how cancer cells respond to their independence in a maladaptive environment. Researchers from the University of Chicago at the Fred Hutch Cancer Center published a new article in the scientific journal Nature describing and analyzing the role of protein synthesis in metastatic cancers.
Using cancer cell lines from animal models and prostate cancer cells from patients, the researchers found that reducing tRNAArg (the tRNA that binds L-arginine) was associated with lower androgen receptor expression. When they examined this correlation, they found that the levels of a gene called SMARCC2 also decreased. SMARCC2 is vital for chromatin structure in cells, and at lower levels, cancer cells become more aggressive. Thus, they identified one of the main elements underlying cell identity disruption in these cancer cells.
The discovery that tRNA reverses lineage plasticity has its next footholds in advancements in therapeutics. Targeted nanoparticle-based approaches to restore tRNA have been suggested following the discovery of this finding, as working with DNA and DNA mutations is often binding and more difficult to handle. In the future, there is the possibility of using tRNA expression levels to measure how a tumor will respond to a drug, or what approach the doctor or medical team may glance towards after evaluating how high the tRNA expression level is. Although this mostly applies to findings about prostate cancer, this shouldn’t be a shortcoming of the field of oncology, as tRNA has its roots in every form of resistance to apoptosis. The better we can understand lineage plasticity and how it impacts the rise and decline of androgen receptors, the more we can improve the diagnostic and clinical outcomes of medicine.
